# Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma

> **NCT06246162** · PHASE1,PHASE2 · RECRUITING · sponsor: **Affiliated Hospital of Nantong University** · enrollment: 30 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lipo-MIT combination regimen

## Key facts

- **NCT ID:** NCT06246162
- **Lead sponsor:** Affiliated Hospital of Nantong University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-13
- **Primary completion:** 2025-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06246162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06246162, "Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT06246162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*